Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor made like a treatment for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Inhibition of galectin-three with GB1211 wasn't relevant to any treatment- or dose-associated developments and https://billm766xis8.eveowiki.com/user